Lymph nodes are the anatomical centers where adaptive immune responses are initiated and amplified. Within each lymph node, resident dendritic cells (DCs), macrophages, and B cells continuously survey incoming lymph for foreign antigens. When vaccine-encoded antigens reach these professional antigen-presenting cells (APCs), they are processed and displayed on MHC class I and II molecules, providing the essential signals for T cell activation. The lymph node's organized architecture — with distinct B cell follicles, T cell zones, and subcapsular sinus macrophage layers — ensures that antigen-bearing APCs encounter cognate lymphocytes within a confined, cytokine-rich microenvironment, dramatically increasing the probability of productive immune recognition. Without sufficient antigen delivery to this centralized hub, even a well-designed vaccine payload may fail to generate protective immunity.
Directing LNP-encapsulated vaccine payloads to the lymph node increases the local antigen concentration available for DC uptake by one to two orders of magnitude relative to systemic circulation. This elevated antigen density drives stronger T cell receptor signaling, more robust clonal expansion, and enhanced polyfunctionality of responding T cells. LN-resident DCs also express high levels of co-stimulatory molecules (CD80, CD86) and pro-inflammatory cytokines that are essential for generating effector and memory T cell populations.
A persistent challenge in LNP vaccine development is disproportionate liver accumulation driven by ApoE adsorption and LDLR-mediated hepatocyte uptake. LN-directed delivery shifts the biodistribution equilibrium toward the intended immunological target. When LNPs are engineered for lymphatic drainage — with particle diameters below 50 nm, near-neutral surface charge, and optimized PEGylation — the fraction of the injected dose reaching the draining lymph node can increase from less than 1% to 5-10% or higher, with a corresponding reduction in hepatic exposure. This redistribution enhances the therapeutic index and enables dose sparing.
The pathways by which LNP vaccines enter the lymph node are collectively influenced by the route of administration, the physicochemical properties of the particles, and the local in vivo microenvironment. The primary route is direct drainage through afferent lymphatic vessels, with cell-mediated active transport serving as a secondary pathway under specific conditions. The detailed mechanisms for each pathway are described below.
Mechanism: Following injection into tissue (intramuscular, subcutaneous, or intradermal), LNPs disperse within the interstitial space and enter the lymphatic circulation directly through afferent lymphatic capillaries. The particles are then carried with the lymph flow to the draining lymph node, where they encounter resident APCs.
Characteristics: This is the fastest and most quantitatively dominant route of LNP entry into the lymph node. Studies have demonstrated that LNPs can reach the draining lymph node within hours of intramuscular injection (as early as 4 hours post-administration), a time frame that precludes cell-mediated transport and confirms reliance on direct lymphatic drainage. The convective flow of interstitial fluid through lymphatic vessels provides a continuous, passive driving force that does not require active biological processes.
Key influencing factors: Particle size is the dominant determinant — LNPs with diameters of approximately 100 nm exhibit optimal lymphatic drainage, while particles exceeding 200 nm are largely retained at the injection site. Surface properties also play a critical role: PEG coatings reduce nonspecific protein adsorption and minimize premature particle clearance by tissue-resident phagocytes, thereby preserving the free LNP population available for lymphatic entry. Zeta potential near neutrality (-10 to +5 mV) further promotes unhindered interstitial diffusion toward lymphatic capillaries.
Mechanism: A fraction of LNPs at the injection site is taken up directly by neighboring immune cells — predominantly DCs, macrophages, and other APCs. These nanoparticle-loaded cells subsequently undergo CCR7-dependent chemotaxis toward CCL19/CCL21 gradients, actively migrating through afferent lymphatic vessels to the draining lymph node. Upon arrival, the cells deposit their LNP cargo directly within the lymph node parenchyma, delivering both the nanoparticle and its antigen payload to the T cell zone.
Characteristics: This pathway is slower than direct lymphatic drainage, as it depends on the kinetics of cellular internalization (typically 2-6 hours), CCR7 upregulation, and active migration (6-24 hours). However, cell-mediated transport achieves anatomically precise delivery: migratory DCs home directly to the paracortex, positioning the LNP cargo in immediate proximity to naive T cells. This spatial precision can partially compensate for the lower overall transport efficiency relative to direct drainage. Additionally, cell-mediated transport accommodates larger particles (>200 nm) that cannot passively enter lymphatic capillaries, broadening the range of LNP formulations amenable to lymph node targeting.
Key influencing factors: The efficiency of cell-mediated transport is governed by the local APC density at the injection site, the phagocytic activity of the resident immune cell population, and the chemokine gradient strength directing cell migration. LNP surface properties that enhance APC recognition — such as moderate positive charge or incorporated targeting ligands — increase the fraction of particles entering this pathway. Co-administration or co-encapsulation of DC-recruiting signals (GM-CSF, specific chemokine gradients) can amplify cell-mediated transport by two- to threefold, increasing the total LN accumulation beyond what passive drainage alone can achieve.
Mechanism: LNPs engineered with specific surface modifications can exploit endogenous carrier proteins to facilitate lymphatic transport. A prominent example is the albumin-recruiting strategy: LNPs incorporating albumin-binding lipids on their surface adsorb endogenous serum albumin, forming LNP-albumin complexes. Albumin is naturally and continuously transported from the bloodstream into the interstitial space and then drained through the lymphatic system via FcRn-mediated transcytosis across lymphatic endothelial cells and SPARC receptor-mediated uptake by APCs. By hitchhiking on this physiological albumin flux, the LNP-albumin complex is efficiently routed toward the lymphatic circulation under the driving force of osmotic and hydrostatic pressure gradients.
Characteristics: This approach leverages a pre-existing, constitutively active transport mechanism without requiring the synthesis of complex targeting ligands or the co-administration of exogenous factors. Albumin-recruiting LNPs have been shown to increase lymph node accumulation by three- to fivefold compared with conventional PEGylated LNPs of equivalent size, while simultaneously reducing off-target liver uptake. Because albumin trafficking is a universal physiological process, this strategy is expected to translate across species and administration routes. The approach also benefits from simplicity: only a single lipid component (the albumin-binding lipid at 2-5 mol%) needs to be incorporated into an otherwise standard LNP formulation.
Key influencing factors: The density and affinity of the albumin-binding lipid determine the fraction of LNPs that successfully recruit albumin in the competitive interstitial environment. Albumin-binding lipid content of 2-5 mol% generally provides optimal lymphatic routing without compromising colloidal stability. The route of administration modulates the availability of interstitial albumin: intradermal and subcutaneous routes, where albumin extravasation from dermal capillaries is continuous, provide a more reliable albumin pool than intramuscular sites with lower vascular density. Patient-specific factors — including serum albumin concentration and lymphatic function — can influence the efficiency of this pathway and may warrant formulation tuning for specific populations.
Passive targeting strategies exploit the natural relationship between LNP physicochemical properties and lymphatic transport efficiency — the same parameters that govern the direct lymphatic drainage pathway described above. By deliberately engineering particle size, surface charge, and PEGylation architecture, formulation scientists can shift the biodistribution equilibrium away from systemic circulation and injection-site retention toward preferential lymph node accumulation. Unlike active targeting approaches that require ligand conjugation, passive strategies rely entirely on tunable formulation parameters and are therefore broadly applicable across payload types and vaccine indications.
The relationship between particle size and lymphatic drainage follows a well-characterized window: particles of approximately 10-100 nm can traverse the interstitial matrix and enter lymphatic capillaries, with the 20-50 nm sub-range providing the most favorable balance of efficient entry and meaningful LN retention. Particles below 10 nm enter lymphatics rapidly but also exit equally rapidly through efferent vessels or enter the blood directly, while particles above 100 nm are physically excluded from the lymphatic capillary gaps and rely on the slower, less efficient cell-mediated pathway. Microfluidic manufacturing platforms — including staggered herringbone micromixers and hydrodynamic flow focusing systems — now enable routine production of LNPs with mean diameters in the 30-80 nm range and polydispersity indices below 0.1, providing the narrow size distributions that reproducible lymphatic targeting demands. For vaccine applications where a fraction of particles exceeding 100 nm is unavoidable (e.g., pDNA-LNPs), combining size optimization with cell-mediated transport enhancement through DC-recruiting signals can partially compensate for the reduced passive drainage.
Table 1. Particle Size Engineering for LN-Targeted LNP Vaccines.
| Size Range | Lymphatic Entry | LN Retention | Formulation Strategy | Recommended Application |
| <10 nm | Rapid | Minimal — rapid blood entry | Avoid; add PEG corona or increase lipid rigidity | Not recommended for LN targeting |
| 20-50 nm | Optimal | Moderate to high — paracortical access | Microfluidic mixing at high flow rate ratio; narrow PDI control | mRNA and saRNA vaccines; DC engagement |
| 50-100 nm | Moderate | High — subcapsular sinus retention | Standard microfluidic or T-junction mixing; moderate PDI acceptable | Protein/peptide antigen delivery; macrophage targeting |
| >100 nm | Low — physically restricted | Variable — depot-dependent | Combine with cell-mediated transport enhancement | pDNA vaccines; depot-formulation designs |
The interstitial extracellular matrix is densely populated with negatively charged proteoglycans and glycosaminoglycans that create an electrostatic barrier to particle mobility. Positively charged LNPs (zeta potential >+10 mV) bind electrostatically to these fixed negative charges, becoming trapped at the injection site with severely restricted diffusion toward lymphatic capillaries. Neutral to slightly negatively charged LNPs (zeta potential between -10 and +5 mV) experience minimal electrostatic hindrance, exhibiting approximately twice the lymph node accumulation of their cationic counterparts. However, a moderately negative charge also reduces the nonspecific APC uptake that initiates the cell-mediated transport pathway, creating a genuine trade-off between interstitial mobility and initial cellular engagement. Charge-reversal strategies offer an elegant resolution: polymers or lipids that transition from anionic at physiological pH to neutral or cationic in the mildly acidic lymphatic microenvironment (pH 6.5-6.8) enable both efficient transport through the interstitium and enhanced cellular internalization upon LN arrival. The ionizable lipid nanoparticles central to mRNA vaccine formulations inherently embody this principle — neutral at pH 7.4 for lymphatic transit, cationic at endosomal pH for membrane disruption.
Table 2. Surface Charge Optimization for Lymphatic Mobility and Cellular Uptake.
| Zeta Potential | Interstitial Mobility | Lymphatic Entry | APC Interaction | Optimization Approach |
| +15 to +30 mV | Poor — electrostatic trapping by matrix proteoglycans | Low | Strong but nonspecific; injection-site APC depletion | Reduce cationic lipid content; introduce PEG shielding |
| -10 to +5 mV | Optimal — minimal electrostatic hindrance | High | Moderate; amenable to ligand-mediated enhancement | Target range for passive LN strategies; pair with active ligands if needed |
| -30 to -10 mV | Good — electrostatic repulsion from matrix | Moderate | Low — repulsion from negatively charged cell surface | Incorporate charge-reversal moiety; add cationic targeting peptide |
| Charge-Reversal | Excellent — anionic during transit | High | Enhanced — cationic upon LN arrival | pH-responsive or enzyme-cleavable charge-switching lipids/polymers |
The PEG coating on the LNP surface serves a dual function that is particularly consequential for lymphatic targeting. First, PEG creates a hydrated steric barrier that prevents particle aggregation and reduces nonspecific protein adsorption during the critical window of interstitial transit — without adequate PEG shielding, LNPs may aggregate upon contact with interstitial matrix proteins and become too large for lymphatic capillary entry. Second, the PEG architecture determines the rate at which LNPs transition from a "stealth" to a "cell-interactive" state. Shorter-chain PEG-lipids (DMG-PEG, C14 anchor) desorb more rapidly from the LNP surface, exposing the underlying lipid membrane for cellular uptake shortly after LN arrival. Longer-chain PEG-lipids (DSG-PEG, C18 anchor) provide more durable shielding, which is advantageous when prolonged lymphatic circulation and drainage to multiple lymph nodes are desired. Pegylated lipid nanoparticles formulated with PEG densities of 1.5-2.5 mol% typically maintain colloidal stability during lymphatic transit without sterically blocking the ligand-receptor interactions needed for subsequent APC engagement. Systematic LNP PEG-lipid optimization can identify the PEG architecture that best reconciles lymphatic mobility with eventual cellular delivery for each specific formulation and administration route.
Table 3. PEGylation Parameter Optimization for LN-Targeted LNP Performance.
| PEG Parameter | Options Evaluated | Impact on Lymphatic Transit | Impact on LN Cellular Uptake | Recommended Window |
| PEG-Lipid Anchor Length | C14 (DMG) to C18 (DSG) | C18: durable shielding, multi-node drainage; C14: faster desorption, single-node preference | C14: rapid membrane exposure, faster uptake; C18: delayed uptake | C14 for rapid single-node delivery; C18 for prolonged multi-node circulation |
| PEG Molar Density | 0.5-10 mol% of total lipid | <1.0 mol%: aggregation risk during transit; >5 mol%: excessive hydration slows diffusion | >5 mol%: steric blockade of receptor engagement and endosomal fusion | 1.5-2.5 mol% for balanced performance |
| PEG Spacer Arm (Ligand Conjugates) | 1-5 kDa PEG between LNP surface and ligand | Minimal direct effect on drainage | 1-2 kDa: optimal for mannose; 2-3.4 kDa: needed for antibody accessibility | 1-2 kDa for small ligands; 2-3.4 kDa for antibodies and scFv |
| PEG Shedding Kinetics | Determined by anchor length and lipid composition | Slower shedding: prolonged stealth; Faster shedding: earlier cell engagement | Faster shedding: earlier membrane exposure and endosomal escape | Match shedding half-life to expected LN transit time (4-24 h) |
BOC Sciences offers comprehensive formulation screening and optimization services to tune LNP size, charge, and surface properties for maximal lymphatic targeting efficiency.
C-type lectin receptors (CLRs) — including the mannose receptor (CD206), DC-SIGN (CD209), and DEC-205 (CD205) — are highly expressed on DCs and macrophages within the lymph node. Mannose-conjugated lipid nanoparticles exploit this recognition system, increasing DC uptake by three- to eightfold compared with unmodified LNPs. Multivalent mannose display with 1-2 kDa PEG spacer arms enables receptor binding pocket access without steric interference. Ligand densities of 2-5 mol% maximize receptor-mediated uptake; densities above 10 mol% induce particle crosslinking and accelerated clearance. Glycan-based targeting extends beyond mannose to Lewis-X-type glycans (DC-SIGN) and fucosylated structures that engage additional CLR family members.
Table 4. Mannose and Glycan Targeting: Receptor, Cell Type, and LN Localization.
| Targeting Ligand | Target Receptor | Target Cell Population | LN Sub-Structure Reached | Reported Uptake Enhancement |
| Mannose / Mannan | CD206 (Mannose Receptor) | DCs, Macrophages | Subcapsular sinus, Medulla | 3-8x vs. unmodified LNP |
| Lewis-X Glycans | DC-SIGN (CD209) | Dermal DCs, LN-Resident DCs | Paracortex, T cell zone | 2-5x vs. unmodified LNP |
| Fucosylated Glycans | DC-SIGN, Langerin | Langerhans cells, Dermal DCs | Paracortex | 2-4x vs. unmodified LNP |
Peptide ligands are chemically defined, scalable, and less immunogenic than antibodies. Peptide-functionalized lipid nanoparticles can engage integrins, scavenger receptors, or chemokine receptors differentially expressed on LN-homing immune cells. CCL21-derived peptides direct LNPs toward CCR7-expressing DCs; phage display-identified peptides such as LyP-1 (lymphatic endothelium) and UNO (CD206) increase LN accumulation by two- to fourfold. Modular conjugation chemistry (maleimide-thiol, click, NHS-ester) allows precise control over ligand orientation and density.
Table 5. Peptide Ligands for LN-Targeted LNP Delivery.
| Peptide Ligand | Target | Mechanism | Reported LN Enhancement |
| CCL21-Derived Peptides | CCR7 on DCs | Mimics natural DC homing signals | 2-3x LN accumulation |
| LyP-1 Peptide | Lymphatic Endothelial Cells | Recognizes lymphatic vessel markers | 2-4x LN accumulation |
| UNO Peptide | CD206 (Mannose Receptor) | Phage display-identified CD206 binder | 3-4x APC-specific uptake |
Antibodies and engineered fragments (scFv, Fab, nanobodies) provide the highest affinity and specificity among targeting ligands. Antibody-conjugated lipid nanoparticles directed against CD40 deliver both LN accumulation and a co-stimulatory signal that enhances DC maturation and T cell priming. Anti-CD3 conjugation directly engages T cells within the LN, bypassing DC-mediated presentation. Bispecific antibody-targeted LNPs simultaneously recognize a DC marker and a lymphocyte marker, promoting immunological synapse formation. Antibody fragments (15-30 kDa) reduce particle size and immunogenicity, making them attractive for multi-dose therapeutic regimens.
Table 6. Antibody and Antibody Fragment Targeting Strategies.
| Targeting Moiety | Target Antigen | Target Cell Type | Functional Benefit |
| Anti-CD40 mAb / scFv | CD40 | DCs, B cells, Macrophages | LN accumulation + co-stimulatory signaling |
| Anti-CD3 mAb / Fab | CD3 | T cells | Direct T cell engagement; bypasses DC requirement |
| Anti-DEC-205 scFv | DEC-205 (CD205) | Cross-presenting CD8+ DCs | Selective delivery to cross-presentation pathway |
| Bispecific (DC + T cell) | CD40 / CD3 | DCs and T cells | Immunological synapse formation; enhanced priming |
Nucleic acid aptamers — structured ssDNA or RNA oligonucleotides selected through SELEX — offer antibody-like affinity with distinct advantages: chemical synthesis with defined molecular weight, site-specific conjugation handles, and minimal immunogenicity. Aptamers targeting CD11c integrin or DEC-205 enhance DC-specific uptake in in vitro and in vivo models with dissociation constants in the low nanomolar range. Because aptamers are nucleic acid-based, they can be co-formulated with mRNA or DNA payloads using compatible chemistry. Stimuli-responsive aptamers that undergo conformational changes in the lymph node microenvironment enable spatially controlled exposure of receptor-binding domains.
Table 7. Aptamer-Based LN Targeting Compared with Antibody and Peptide Approaches.
| Feature | Aptamers | Antibodies | Peptides |
| Molecular Weight | 8-25 kDa | ~150 kDa (IgG); 15-30 kDa (scFv) | 1-5 kDa |
| Affinity (Kd) | Low nM to pM | pM to low nM | nM to low μM |
| Immunogenicity | Minimal | Moderate to high (full mAb); Low (fragments) | Low |
| Conjugation Chemistry | Terminal amine/thiol; click chemistry | Lysine, cysteine; site-specific engineering | N/C-terminal cysteine; click chemistry |
| Stimuli-Responsive Design | Inherent — conformational switching | Limited | Limited |
This strategy exploits the natural lymphatic trafficking of endogenous albumin, which is continuously transported from blood to interstitium and drained through lymphatics via FcRn and SPARC receptor-mediated uptake. By incorporating albumin-binding lipids into the LNP surface, nanoparticles "hitchhike" on albumin, increasing LN accumulation by three- to fivefold while reducing liver uptake. The albumin-recruiting approach requires no complex targeting ligand synthesis and leverages a pre-existing physiological mechanism, making it one of the most actively investigated LN-targeting strategies in recent research.
Table 8. Albumin-Recruiting Strategy: Mechanism, Performance, and Comparison.
| Parameter | Albumin-Recruiting LNP | Conventional PEGylated LNP |
| Targeting Mechanism | Endogenous albumin hitchhiking via FcRn/SPARC | Passive drainage via size and charge |
| LN Accumulation (Fold vs. IV Bolus) | 3-5x increase | 1-2x increase (size-dependent) |
| Liver Uptake | Reduced — lymphatic routing preference | High — ApoE/LDLR-mediated |
| Ligand Synthesis Required | No — albumin-binding lipid only | No |
| Key Limitation | Albumin competition; patient albumin variability | Size and charge constraints; liver dominance |
BOC Sciences can help determine whether ligand-mediated targeting is needed and support ligand selection, surface conjugation, density optimization, and APC-specific delivery evaluation.
The choice of vaccine payload fundamentally shapes the LN targeting strategy, as each payload class imposes distinct requirements for encapsulation, intracellular delivery, and antigen expression kinetics.
For mRNA delivery to the lymph node, the LNP must protect mRNA from extracellular RNase degradation during lymphatic transit, facilitate APC uptake, and promote endosomal escape. Ionizable lipids with an apparent pKa of 6.2-6.5 are critical — they become protonated in the acidifying endosome, triggering membrane disruption and cytosolic mRNA release. Optimized formulations achieve endosomal escape efficiencies of 5-15%, versus less than 1% for early-generation LNPs. Modified nucleosides (pseudouridine, N1-methylpseudouridine) and codon optimization further enhance translational output in the LN microenvironment.
saRNA encodes both the antigen and alphavirus replicase machinery, enabling 100- to 1000-fold intracellular RNA amplification. This makes saRNA ideal for LN delivery: a modest number of successfully delivered molecules can generate sustained, high-level antigen expression over 7-14 days, potentially eliminating booster doses. Lipid nanoparticles for saRNA delivery require adjusted N/P ratios to accommodate the larger cargo (9-12 kb vs. 2-4 kb for mRNA) while maintaining particle size within the lymphatic-accessible range.
DNA vaccines offer exceptional stability but face the additional nuclear delivery barrier. Lipid nanoparticles for pDNA delivery to the lymph node must incorporate nuclear localization signals or leverage nuclear entry during DC mitosis. The larger hydrodynamic diameter of pDNA-LNPs (80-120 nm) places them at the upper limit of passive lymphatic drainage, making cell-mediated transport or active targeting strategies particularly important. Modern ionizable lipids — neutral at physiological pH, cationic only in acidic endosomes — overcome the cytotoxicity and nonspecific binding issues of early-generation permanently cationic lipids.
Lipid nanoparticles for antigen delivery address a fundamentally different challenge: protein antigens must be presented in their native or processed form on MHC molecules, not translated intracellularly. LNPs can release cargo extracellularly in the LN (for uptake and processing by resident APCs) or deliver protein directly into the DC cytoplasm (for MHC class I cross-presentation). Encapsulation must preserve conformational epitopes, and co-encapsulation with TLR or STING agonists creates self-adjuvanted vaccines concentrating antigen and adjuvant in the same LN compartment.
Short synthetic peptides (8-25 amino acids) enable precise epitope targeting but are inherently difficult to encapsulate due to small size and high aqueous solubility. LNP-based peptide delivery strategies include lipophilic modification (palmitoylation, cholesterol conjugation) to anchor peptides within the lipid bilayer, co-formulation with anionic helper lipids for electrostatic retention, and peptide-polymer conjugates that increase hydrodynamic size. Peptides with intermediate MHC affinity (IC50 50-500 nM) benefit most from LN-targeted delivery, as their presentation is limited by availability rather than intrinsic binding capacity.
The LN microenvironment can be conditioned through co-delivery of TLR7/8 agonists, TLR9 agonists (CpG), or STING activators that trigger local cytokine production and DC maturation. LN-restricted adjuvant delivery achieves comparable or superior immune enhancement to systemic administration with substantially reduced inflammatory toxicity. Lipid nanoparticles for co-delivery of antigen and adjuvant within the same particle ensure the APC simultaneously receives both the antigen and the maturation signal — a requirement for productive priming. This co-delivery approach increases antigen-specific T cell responses by 5-20-fold versus separate administration.
Table 9. Payload-Specific LN Targeting Strategy Summary.
| Payload Type | Key LN Delivery Challenge | Critical Formulation Parameter | Preferred Targeting Mode | Typical Particle Size |
| mRNA | RNase degradation; endosomal escape | Ionizable lipid pKa 6.2-6.5; N/P ratio 4-8 | Passive + DC-targeted | 40-80 nm |
| saRNA | Large cargo size (9-12 kb); sustained expression | Adjusted N/P ratio; lipid composition | Passive + albumin-recruiting | 50-100 nm |
| pDNA | Nuclear delivery; large particle size | NLS incorporation; ionizable lipid selection | Cell-mediated + active targeting | 80-120 nm |
| Protein Antigen | Conformational integrity; MHC presentation route | Encapsulation method; release kinetics | Passive + B cell follicle targeting | 50-100 nm |
| Peptide Antigen | Small size; rapid diffusion; MHC affinity | Lipophilic anchor; electrostatic retention | Active DC targeting | 30-80 nm |
| Adjuvant | Systemic toxicity; spatiotemporal coordination | Co-encapsulation with antigen | Co-delivery with antigen payload | Matched to antigen LNP |
Based on your vaccine payload, delivery route, target immune cells, and research objectives, BOC Sciences designs and produces customized LN-targeted LNPs with appropriate formulation, encapsulation, and surface engineering strategies.
Cause: LNPs are retained at the injection site and fail to reach the draining lymph node. Primary causes include particle size exceeding 100 nm, colloidal instability in the interstitial environment, or aggregation upon contact with interstitial matrix components.
Indicator: DLS in simulated interstitial fluid reveals PDI >0.2 or mean diameter >100 nm; IVIS imaging shows dominant injection site signal with negligible LN signal at 6-24 hours.
Proposed Solution: Reduce particle size to 30-50 nm by adjusting microfluidic mixing parameters (total flow rate, flow rate ratio, post-mixing dilution). Review PEG-lipid content: <1.0 mol% may provide insufficient stabilization; >3.0 mol% impedes membrane fusion. If aggregation persists, screen alternative helper lipids or replace PEG-lipid anchor (e.g., C14 to C18 dialkyl anchors).
Cause: LNPs accumulate in the lymph node (confirmed by IVIS or tissue quantification) but show minimal APC association on flow cytometry. Dense PEG coating sterically blocks interaction with cell surface receptors despite successful lymphatic drainage.
Indicator: LN signal present by IVIS; flow cytometry of digested LN shows<5% of LNP signal associated with DCs or macrophages.
Proposed Solution: Introduce mannose-terminated PEG-lipids (mannose at distal end of 1-2 kDa PEG spacer) at 2-5 mol% for DC/macrophage targeting, or antibody fragments (scFv, nanobodies) for higher-specificity APC subset engagement. Titrate PEG spacer length to balance ligand accessibility with colloidal stability.
Cause: Robust APC uptake (high fluorescence or radiolabel signal in DCs/macrophages) accompanied by negligible functional payload expression. The LNP is internalized but the payload is degraded in the endolysosomal compartment. Primary cause is suboptimal ionizable lipid performance.
Indicator: High LAMP1 co-localization by confocal microscopy; low reporter gene expression or antigen production despite high cellular uptake; galectin recruitment assay shows minimal membrane disruption.
Proposed Solution: Target ionizable lipid pKa of 6.2-6.5 (below 6.0: insufficient protonation; above 6.8: premature protonation and toxicity). Increase ionizable lipid mole fraction from 40-50 mol% to 50-60 mol%. Incorporate fusogenic helper lipid DOPE in place of or in addition to DSPC to promote hexagonal phase transition required for membrane fusion.
Cause: Liver accumulation dominates the biodistribution profile due to ApoE adsorption onto the LNP surface and subsequent LDLR-mediated hepatocyte uptake. Splenic signal may reflect filtration of aggregated particles.
Indicator: Liver %ID/g exceeds LN %ID/g by >5-fold; spleen signal >2-fold above LN signal; LN-to-liver ratio<0.1.
Proposed Solution: Reduce particle size below 50 nm to decrease Kupffer cell and hepatocyte recognition. Switch from intravenous to subcutaneous or intradermal administration — these routes deliver LNPs first to lymphatics rather than directly to the bloodstream. Incorporate albumin-binding lipid at 2-5 mol% to route LNPs toward lymphatic rather than hepatic clearance. Modulate surface charge toward neutral or slightly negative (-5 to -10 mV zeta potential) to reduce ApoE adsorption, decreasing liver accumulation by 30-50%.
BOC Sciences provides systematic troubleshooting and optimization services to resolve lymphatic drainage, endosomal escape, and biodistribution issues.
BOC Sciences provides comprehensive support for LN-targeted LNP vaccine development, beginning with strategic selection of the most appropriate targeting approach for each project's immunological objectives. Whether the goal is broad DC engagement through passive size and charge optimization, receptor-specific delivery via mannose or antibody conjugation, or exploitation of endogenous albumin trafficking pathways, our team works collaboratively with clients to define a targeting strategy grounded in the biological requirements of the vaccine indication. Lymph node-targeted LNP development at BOC Sciences encompasses formulation design across the full range of lipid compositions, particle architectures, and surface engineering approaches, with iterative refinement based on characterization feedback. Our targeted LNP development platform integrates passive and active targeting elements into a unified formulation design.
Each payload class imposes distinct requirements for encapsulation chemistry and stability management. For nucleic acid payloads, our nucleic acid encapsulation in LNPs services employ ionizable lipid-based formulations with N/P ratios optimized for each nucleic acid species. For protein and peptide antigens, we offer protein encapsulation and peptide encapsulation services using remote loading, lipid film hydration, or microfluidic methods. Co-encapsulation of multiple payloads ensures antigen and adjuvant are incorporated within the same particle population for spatiotemporally coordinated delivery.
Nanoparticle functionalization services at BOC Sciences encompass the full spectrum of ligand conjugation chemistries. Mannose and carbohydrate ligands are conjugated via PEG-lipid intermediates with controlled spacer lengths and surface densities. Antibodies and antibody fragments are conjugated through maleimide-thiol, copper-free click, or NHS-ester chemistry with purification steps ensuring homogeneous surface presentation. Peptide ligands are synthesized with terminal handles for site-specific conjugation, and aptamers are functionalized with lipid anchors for spontaneous LNP surface insertion. Ligand density is quantified and optimized for each approach.
BOC Sciences offers a complete suite of nanoparticle analysis and characterization services tailored to LN-targeted LNP vaccines. Physicochemical characterization includes DLS, zeta potential, cryo-EM, and NTA. Encapsulation efficiency and payload integrity are assessed using payload-specific methods. Nanoparticle cellular uptake testing provides quantitative dose-response data in primary DCs and APC lines, while nanoparticle intracellular localization detection by confocal microscopy reveals whether internalized LNPs progress toward productive cytoplasmic delivery or lysosomal degradation.
BOC Sciences provides integrated nanoparticle in vivo imaging services and nanoparticle cellular and in vivo evaluation for LN-targeted vaccines. In vivo biodistribution studies using IVIS or quantitative tissue analysis provide organ-level and LN-level accumulation data. Immune response evaluation encompasses serum antibody quantification (ELISA, neutralization assays), T cell profiling (MHC multimer, intracellular cytokine staining, ELISpot), and germinal center analysis (flow cytometry, immunohistochemistry). The integration of biodistribution and immunological data enables PK-PD relationship construction guiding formulation optimization and candidate selection.
Table 10. BOC Sciences Services for LN-Targeted LNP Vaccine Development.
| Service | Scope of Service | Key Deliverables | Inquiry |
| LN-Targeted LNP Formulation Design | Targeting strategy selection, lipid composition screening, passive and active targeting integration, formulation optimization for lymphatic drainage | Optimized lead formulations with defined size, PDI, zeta potential, and EE%; formulation development report | Inquiry |
| Ionizable Lipid Screening and Optimization | Library-based screening of 50-200+ ionizable lipids, pKa determination, endosomal escape evaluation, structure-activity relationship analysis | Ranked lipid candidates with pKa, EE%, and endosomal escape data; recommended lead lipid | Inquiry |
| PEG-Lipid Engineering and Optimization | PEG chain length screening, PEG density titration, shedding kinetics analysis, stability and aggregation assessment | Optimized PEG-lipid architecture; formulation stability report | Inquiry |
| Mannose and Glycan Conjugation Services | Mannose-PEG-lipid synthesis, ligand density optimization, receptor binding validation, APC uptake quantification | Mannose-functionalized LNPs with validated receptor binding; cellular uptake data | Inquiry |
| Antibody and Antibody Fragment Conjugation | scFv, Fab, nanobody, and full antibody conjugation; site-specific and random conjugation; unconjugated ligand removal and QC | Antibody-conjugated LNPs with defined ligand-to-particle ratio; binding specificity data | Inquiry |
| Endosomal Escape Assessment | Galectin recruitment assay, lysosomal co-localization analysis, functional payload expression quantification | Endosomal escape efficiency data; correlation with functional expression outcomes | Inquiry |
| In Vivo LN Biodistribution and Immune Evaluation | IVIS fluorescence imaging, quantitative tissue biodistribution, LN cell-type association, antibody titer and T cell response profiling | Comprehensive biodistribution and immunogenicity report; PK-PD correlation analysis | Inquiry |
| LNP Manufacturing and Process Development | Microfluidic process optimization, scale-up from milligram to gram quantities, PAT integration, batch consistency validation | Scalable manufacturing process with defined CPPs; multiple development batches with QC data | Inquiry |
Lymph node targeting has emerged as a defining design principle for next-generation LNP-based vaccines, offering a mechanistic pathway to enhance potency and safety through precise spatial control of antigen and adjuvant delivery. The integration of passive targeting parameters — particle size in the 20-50 nm range, near-neutral surface charge, optimized PEGylation, and lymphatic-favoring administration routes — with active targeting ligands spanning mannose, peptide, antibody, aptamer, and albumin-recruiting strategies creates a multidimensional design space that can be systematically explored for each vaccine payload and indication. mRNA, saRNA, DNA, protein, peptide, and adjuvant cargos each impose distinct encapsulation and delivery requirements that must be addressed within a unified LN-directed framework. For research teams navigating the complexities of LN-targeted LNP vaccine development, BOC Sciences offers integrated scientific support from targeting strategy design through formulation development, ligand conjugation, comprehensive characterization, and in vivo evaluation, enabling the translation of lymph node targeting concepts into functionally validated vaccine candidates ready for further development.
References
